MINI FUTURE LONG - LIGAND PHARMACEUTICALS Stock

Certificat

DE000ME5TTQ4

Real-time Bid/Ask 05:09:59 2024-06-14 am EDT
2.47 EUR / 2.66 EUR +6.43% Intraday chart for MINI FUTURE LONG - LIGAND PHARMACEUTICALS
Current month-14.84%
1 month-13.31%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-14 2.48 +2.90%
24-06-13 2.41 -0.41%
24-06-12 2.42 +5.22%
24-06-11 2.3 -1.71%
24-06-10 2.34 -6.77%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 04:08 am EDT

More quotes

Static data

Product typeCertificat Turbo Stop Loss
Buy / SellCALL
Underlying LIGAND PHARMACEUTICALS INCORPORATED
Issuer Morgan Stanley
WKN ME5TTQ
ISINDE000ME5TTQ4
Date issued 2023-12-20
Strike 54.75 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.56
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.41
Lowest since issue 1.35
Spread 0.19
Spread %7.12%

Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Sector
-
More about the company

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Ligand Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
81.34 USD
Average target price
116.8 USD
Spread / Average Target
+43.59%
Consensus